Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mitotic Index Thresholds Do Not Predict Clinical Outcome for IDH-Mutant Astrocytoma

14 Aug 2019

Abstract excerpt

Current histological grading recommendations for isocitrate dehydrogenase (IDH)-mutant astrocytoma are imprecise and not reliably predictive of patient outcome, while somatic copy number alterations are emerging as important prognostic biomarkers. One explanation for this relative underperformance of histological grading is that current criteria to distinguish World Health Organization (WHO) grade III anaplastic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Glioma Diagnosis and Treatment
Share to Meningioma and schwannoma management
Share to Ocular Oncology and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31529048
DOI: 10.1093/jnen/nlz082

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mitotic Index Thresholds Do Not Predict Clinical Outcome for IDH-Mutant AstrocytomaPMID 31529048Read ↗

Mitotic count is prognostic in IDH mutant astrocytoma without homozygous deletion of CDKN2A/B. Results of consensus panel review of EORTC trial 26053 (CATNON) and EORTC trial 22033-26033.Semantic proximity Read ↗

A threshold for mitotic activity and post-surgical residual volume defines distinct prognostic groups for astrocytoma IDH-mutant.Semantic proximity Read ↗

IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas.Semantic proximity Read ↗

Integrated assessment of malignancy in IDH‐mutant astrocytoma with p16 and methylthioadenosine phosphorylase immunohistochemistrySemantic proximity Read ↗

The role of apparent diffusion coefficient in the grading of adult isocitrate dehydrogenase-mutant astrocytomas: relationship with the Ki-67 proliferation index.Semantic proximity Read ↗

A novel grading system combining histological grade and CDKN2A homozygous and hemizygous deletion to predict prognosis in IDH-mutant astrocytoma.Semantic proximity Read ↗

Evolutionary trajectories of IDH-mutant astrocytoma identify molecular grading markers related to cell cyclingSemantic proximity Read ↗

IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO.Semantic proximity Read ↗

Supratentorial grade II astrocytoma: biological features and clinical course.Semantic proximity Read ↗

Ki-67 proliferation index but not mitotic thresholds integrates the molecular prognostic stratification of lower grade gliomasSemantic proximity Read ↗

T2-FLAIR mismatch sign in nonenhancing astrocytoma, IDH-mutant: impact of tumor area on diagnostic sensitivity.Semantic proximity Read ↗

CDKN2A/B deletion in IDH-mutant astrocytomas: An evaluation by Fluorescence in-situ hybridization.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.